Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg

27 listopada 2013 zaktualizowane przez: Boehringer Ingelheim

A 16-week Randomised, Placebo-controlled, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol From the Hydrofluoroalkane Metered Dose Inhaler (2 Actuations of 25 Mcg Twice Daily) in Moderate Persistent Asthma Patients With the B16-Arg/Arg Genotype

This is a 16 week multicentre, multinational, randomised, double-blind, double-dummy, placebo-controlled, parallel group study to evaluate the long-term efficacy and safety of tiotropium compared to salmeterol in moderate persistent asthmatic (GINA step 3) patients homozygous for arginine at the 16th amino acid position of the beta-adrenergic receptor (ADRB2). Following an initial 4-week run-in period on salmeterol MDI patients will be randomised into the 16 week double-blind treatment period in which they receive either tiotropium once daily administered from the Respimat inhaler or salmeterol twice daily administered from the hydrofluoro-alkane Metered Dose Inhaler (MDI), or placebo twice daily. After the 16 week treatment period all patients will receive salmeterol MDI twice daily for four weeks.

The patients perform daily morning and evening peak flow (PEF) and Forced Expiratory Volume in the First Second (FEV1) measurements with an electronic peak flow meter throughout the study. Daily data on asthma control and use of rescue medication are recorded using an electronic diary included in the electronic peak flow meter. On study visits the Mini-Asthma Quality of Life Questionnaire (Elizabeth Juniper) is administered, pulse and blood pressure and pre-dose pulmonary function testing (FEV1 and Forced Vital Capacity) are performed.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

388

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Afryka Południowa
      • Bellville, Afryka Południowa
        • 205.342.27002 Boehringer Ingelheim Investigational Site
      • Bloemfontein, Afryka Południowa
        • 205.342.27008 Boehringer Ingelheim Investigational Site
      • Cape Town, Afryka Południowa
        • 205.342.27001 Boehringer Ingelheim Investigational Site
      • Cape Town, Afryka Południowa
        • 205.342.27004 Boehringer Ingelheim Investigational Site
      • Centurion, Afryka Południowa
        • 205.342.27006 Boehringer Ingelheim Investigational Site
      • Durban, Afryka Południowa
        • 205.342.27003 Boehringer Ingelheim Investigational Site
      • George, Afryka Południowa
        • 205.342.27007 Boehringer Ingelheim Investigational Site
      • Pretoria, Afryka Południowa
        • 205.342.27005 Boehringer Ingelheim Investigational Site
  • Austria
      • Graz, Austria
        • 205.342.43002 Boehringer Ingelheim Investigational Site
      • Trofaiach, Austria
        • 205.342.43004 Boehringer Ingelheim Investigational Site
      • Wels, Austria
        • 205.342.43003 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 205.342.43001 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 205.342.43005 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 205.342.43006 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 205.342.43007 Boehringer Ingelheim Investigational Site
  • Belgia
      • Anderlecht, Belgia
        • 205.342.32010 Boehringer Ingelheim Investigational Site
      • Angleur, Belgia
        • 205.342.32005 Boehringer Ingelheim Investigational Site
      • Brussel, Belgia
        • 205.342.32002 Boehringer Ingelheim Investigational Site
      • Bruxelles, Belgia
        • 205.342.32007 Boehringer Ingelheim Investigational Site
      • Bruxelles, Belgia
        • 205.342.32014 Boehringer Ingelheim Investigational Site
      • Gent, Belgia
        • 205.342.32001 Boehringer Ingelheim Investigational Site
      • Herentals, Belgia
        • 205.342.32003 Boehringer Ingelheim Investigational Site
      • Malmédy, Belgia
        • 205.342.32004 Boehringer Ingelheim Investigational Site
      • Menen, Belgia
        • 205.342.32012 Boehringer Ingelheim Investigational Site
      • Montigny-le-Tilleul, Belgia
        • 205.342.32006 Boehringer Ingelheim Investigational Site
      • Namur, Belgia
        • 205.342.32009 Boehringer Ingelheim Investigational Site
      • Turnhout, Belgia
        • 205.342.32011 Boehringer Ingelheim Investigational Site
      • Yvoir, Belgia
        • 205.342.32013 Boehringer Ingelheim Investigational Site
  • Dania
      • Aalborg, Dania
        • 205.342.45003 Boehringer Ingelheim Investigational Site
      • Hvidovre, Dania
        • 205.342.45001 Boehringer Ingelheim Investigational Site
      • Kobenhavn NV, Dania
        • 205.342.45002 Boehringer Ingelheim Investigational Site
      • Odense C, Dania
        • 205.342.45004 Boehringer Ingelheim Investigational Site
  • Federacja Rosyjska
      • Moscow, Federacja Rosyjska
        • 205.342.07001 Boehringer Ingelheim Investigational Site
      • Moscow, Federacja Rosyjska
        • 205.342.07002 Boehringer Ingelheim Investigational Site
      • Moscow, Federacja Rosyjska
        • 205.342.07003 Boehringer Ingelheim Investigational Site
      • Moscow, Federacja Rosyjska
        • 205.342.07004 Boehringer Ingelheim Investigational Site
      • Moscow, Federacja Rosyjska
        • 205.342.07005 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Federacja Rosyjska
        • 205.342.07006 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Federacja Rosyjska
        • 205.342.07007 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Federacja Rosyjska
        • 205.342.07008 Boehringer Ingelheim Investigational Site
  • Finlandia
      • Helsinki, Finlandia
        • 205.342.35803 Boehringer Ingelheim Investigational Site
      • Jyväskylä, Finlandia
        • 205.342.35801 Boehringer Ingelheim Investigational Site
      • Lahti, Finlandia
        • 205.342.35802 Boehringer Ingelheim Investigational Site
      • Tampere, Finlandia
        • 205.342.35804 Boehringer Ingelheim Investigational Site
  • Francja
      • Brest, Francja
        • 205.342.3305A Centre Hosp de la Cavale Blanche
      • Chamalières, Francja
        • 205.342.3304A Cabinet Médical
      • Chauny, Francja
        • 205.342.3307A Boehringer Ingelheim Investigational Site
      • Grenoble, Francja
        • 205.342.3301A UCP-X - Clinique Médicale
      • Montpellier, Francja
        • 205.342.3302A Hôpital Arnaud de Villeneuve
      • Poitiers, Francja
        • 205.342.3306A Mediscis
      • Saint Pierre la Réunion, Francja
        • 205.342.3308A Boehringer Ingelheim Investigational Site
      • Saint Pierre la Réunion, Francja
        • 205.342.3308B Boehringer Ingelheim Investigational Site
  • Grecja
      • Athens, Grecja
        • 205.342.30001 Boehringer Ingelheim Investigational Site
      • Athens, Grecja
        • 205.342.30002 Boehringer Ingelheim Investigational Site
      • Heraklion, Grecja
        • 205.342.30005 Boehringer Ingelheim Investigational Site
      • Kavala, Grecja
        • 205.342.30006 Boehringer Ingelheim Investigational Site
      • Larisa, Grecja
        • 205.342.30004 Boehringer Ingelheim Investigational Site
      • Thessaloniki, Grecja
        • 205.342.30003 Boehringer Ingelheim Investigational Site
  • Hiszpania
      • Barcelona, Hiszpania
        • 205.342.34006 Hospital Clinic i Provincial de Barcelona
      • Centelles, Hiszpania
        • 205.342.34011 Boehringer Ingelheim Investigational Site
      • Guadalajara, Hiszpania
        • 205.342.34004 Hospital General Universitario de Guadalajara
      • Las Palmas de Gran Canaria, Hiszpania
        • 205.342.34002 Hospital de Gran Canaria Dr. Negrín
      • Lleida, Hiszpania
        • 205.342.34007 Hospital Universitari Arnau de Vilanova
      • Madrid, Hiszpania
        • 205.342.34003 Hospital Universitario La Paz
      • Madrid, Hiszpania
        • 205.342.34009 Hospital Universio Puerta del Hierro
      • Santander, Hiszpania
        • 205.342.34008 Hospital Universitario Marqués de Valdecilla
      • Sevilla, Hiszpania
        • 205.342.34005 Hospital Vírgen de la Macarena
      • Valencia, Hiszpania
        • 205.342.34010 Hospital General Universitario de Valencia
  • Indyk
      • Ankara, Indyk
        • 205.342.90001 Boehringer Ingelheim Investigational Site
      • Ankara, Indyk
        • 205.342.90006 Boehringer Ingelheim Investigational Site
      • Bursa, Indyk
        • 205.342.90003 Boehringer Ingelheim Investigational Site
      • Istanbul, Indyk
        • 205.342.90007 Istanbul Universitesi Cerrahpasa Tip Fakultesi
      • Izmit, Indyk
        • 205.342.90005 Kocaeli Universitesi Tip Fakultesi
      • Manisa, Indyk
        • 205.342.90004 Celal Bayar Universitesi Tip Fakultesi
  • Niemcy
      • Beelitz-Heilstätten, Niemcy
        • 205.342.49016 Boehringer Ingelheim Investigational Site
      • Berlin, Niemcy
        • 205.342.49004 Boehringer Ingelheim Investigational Site
      • Berlin, Niemcy
        • 205.342.49006 Boehringer Ingelheim Investigational Site
      • Berlin, Niemcy
        • 205.342.49013 Boehringer Ingelheim Investigational Site
      • Bruchsal, Niemcy
        • 205.342.49003 Boehringer Ingelheim Investigational Site
      • Frankfurt/Main, Niemcy
        • 205.342.49011 Boehringer Ingelheim Investigational Site
      • Kassel, Niemcy
        • 205.342.49007 Boehringer Ingelheim Investigational Site
      • Köln, Niemcy
        • 205.342.49009 Boehringer Ingelheim Investigational Site
      • Mainz, Niemcy
        • 205.342.49010 Boehringer Ingelheim Investigational Site
      • Minden, Niemcy
        • 205.342.49008 Boehringer Ingelheim Investigational Site
      • Neuruppin, Niemcy
        • 205.342.49015 Boehringer Ingelheim Investigational Site
      • Rathenow, Niemcy
        • 205.342.49012 Boehringer Ingelheim Investigational Site
      • Rüdersdorf, Niemcy
        • 205.342.49005 Boehringer Ingelheim Investigational Site
      • Weinheim, Niemcy
        • 205.342.49002 Boehringer Ingelheim Investigational Site
  • Słowacja
      • Banska Bystrica, Słowacja
        • 205.342.42101 Boehringer Ingelheim Investigational Site
      • Bratislava, Słowacja
        • 205.342.42102 Boehringer Ingelheim Investigational Site
      • Bratislava, Słowacja
        • 205.342.42104 Boehringer Ingelheim Investigational Site
      • Bratislava, Słowacja
        • 205.342.42105 Boehringer Ingelheim Investigational Site
      • Bratislava, Słowacja
        • 205.342.42107 Boehringer Ingelheim Investigational Site
      • Kosice, Słowacja
        • 205.342.42103 Boehringer Ingelheim Investigational Site
      • Trencin, Słowacja
        • 205.342.42106 Boehringer Ingelheim Investigational Site
      • Zilina, Słowacja
        • 205.342.42108 Boehringer Ingelheim Investigational Site
  • Włochy
      • Ferrara, Włochy
        • 205.342.39003 Azienda Ospedaliera " S. Anna"
      • Firenze, Włochy
        • 205.342.39006 Azienda Ospedaliera Universitaria Careggi
      • Genova, Włochy
        • 205.342.39005 Ospedale San Martino
      • Modena, Włochy
        • 205.342.39002 Università di Modena e Reggio Emilia
      • Orbassano (to), Włochy
        • 205.342.39010 Boehringer Ingelheim Investigational Site
      • Pavia, Włochy
        • 205.342.39007 Policlinico San Matteo
      • Pisa, Włochy
        • 205.342.39001 Ospedale di Cisanello
      • Sesto San Giovanni (mi), Włochy
        • 205.342.39009 Boehringer Ingelheim Investigational Site
  • Zjednoczone Królestwo
      • Aylesbury, Zjednoczone Królestwo
        • 205.342.44002 Boehringer Ingelheim Investigational Site
      • Chertsey, Zjednoczone Królestwo
        • 205.342.44001 Boehringer Ingelheim Investigational Site
      • Greenisland, Zjednoczone Królestwo
        • 205.342.44003 Boehringer Ingelheim Investigational Site
      • Leicester, Zjednoczone Królestwo
        • 205.342.44006 Boehringer Ingelheim Investigational Site
      • Nottingham, Zjednoczone Królestwo
        • 205.342.44005 Boehringer Ingelheim Investigational Site

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion_Criteria:

  1. Patients homozygous for arginine at the 16th amino acid position of the beta2 adrenergic receptor (B16 Arg/Arg)
  2. All patients must sign and date an Informed Consent Form for the study prior to participation in the trial
  3. Male or female outpatients with at least 18 years of age, but not older than 65 years
  4. Patients must have a documented history of asthma
  5. Patients must be current non-smokers or ex-smokers with a cigarette smoking history of <10 pack-years
  6. Patients must be on a maintenance treatment with inhaled corticosteroids with a total daily dose of 400 - 1000 mcg budesonide or equivalent

Exclusion_Criteria:

  1. Patients with a significant disease other than asthma
  2. Patients with a recent history (i.e., six months or less) of myocardial infarction
  3. Patients who have been hospitalized for heart failure (New York Heart Association class III or IV) within the past year
  4. Patients with any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year
  5. Patients with malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed.
  6. Patients with a diagnosis of chronic obstructive pulmonary disease (COPD)
  7. Patients with a history of life threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis
  8. Patients with known active tuberculosis
  9. Patients who have undergone thoracotomy with pulmonary resection.
  10. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to visit 1 or patients who are currently in a pulmonary rehabilitation program that will not be maintained throughout the duration of the study.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Model interwencyjny: Przydział równoległy

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in Mean Weekly Morning Peak Expiratory Flow From Baseline to the End of the Trial
Ramy czasowe: baseline and after 16 weeks of treatment
Change from baseline in mean weekly morning peak expiratory flow at 16 weeks. Baseline is defined as the last week prior to the randomisation visit
baseline and after 16 weeks of treatment

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Mean Weekly Morning Peak Expiratory Flow at Week 4
Ramy czasowe: After 4 weeks of treatment
Mean weekly morning peak expiratory flow at week 4, pre-dose
After 4 weeks of treatment
Mean Weekly Morning Peak Expiratory Flow at Week 8
Ramy czasowe: After 8 weeks of treatment
Mean weekly morning peak expiratory flow at week 8, pre-dose
After 8 weeks of treatment
Mean Weekly Morning Peak Expiratory Flow at Week 12
Ramy czasowe: After 12 weeks of treatment
Mean weekly morning peak expiratory flow at week 12, pre-dose
After 12 weeks of treatment
Mean Weekly Morning Peak Expiratory Flow at Week 16
Ramy czasowe: After 16 weeks of treatment
Mean weekly morning peak expiratory flow at week 16, pre-dose
After 16 weeks of treatment
Mean Weekly Evening Peak Expiratory Flow at Week 4
Ramy czasowe: After 4 weeks of treatment
Mean weekly evening peak expiratory flow at week 4, pre-dose
After 4 weeks of treatment
Mean Weekly Evening Peak Expiratory Flow at Week 8
Ramy czasowe: After 8 weeks of treatment
Mean weekly evening peak expiratory flow at week 8, pre-dose
After 8 weeks of treatment
Mean Weekly Evening Peak Expiratory Flow at Week 12
Ramy czasowe: After 12 weeks of treatment
Mean weekly evening peak expiratory flow at week 12, pre-dose
After 12 weeks of treatment
Mean Weekly Evening Peak Expiratory Flow at Week 16
Ramy czasowe: After 16 weeks of treatment
Mean weekly evening peak expiratory flow at week 16, pre-dose
After 16 weeks of treatment
Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 4
Ramy czasowe: After 4 weeks of treatment
Mean weekly morning forced expiratory volume in 1 second at week 4, pre-dose
After 4 weeks of treatment
Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 8
Ramy czasowe: After 8 weeks of treatment
Mean weekly morning forced expiratory volume in 1 second at week 8, pre-dose
After 8 weeks of treatment
Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 12
Ramy czasowe: After 12 weeks of treatment
Mean weekly morning forced expiratory volume in 1 second at week 12, pre-dose
After 12 weeks of treatment
Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 16
Ramy czasowe: After 16 weeks of treatment
Mean weekly morning forced expiratory volume in 1 second at week 16, pre-dose
After 16 weeks of treatment
Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 4
Ramy czasowe: After 4 weeks of treatment
Mean weekly evening forced expiratory volume in 1 second at week 4, pre-dose
After 4 weeks of treatment
Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 8
Ramy czasowe: After 8 weeks of treatment
Mean weekly evening forced expiratory volume in 1 second at week 8, pre-dose
After 8 weeks of treatment
Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 12
Ramy czasowe: After 12 weeks of treatment
Mean weekly evening forced expiratory volume in 1 second at week 12, pre-dose
After 12 weeks of treatment
Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 16
Ramy czasowe: After 16 weeks of treatment
Mean weekly evening forced expiratory volume in 1 second at week 16, pre-dose
After 16 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 4
Ramy czasowe: After 4 weeks of treatment
Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value
After 4 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 8
Ramy czasowe: After 8 weeks of treatment
Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value
After 8 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 12
Ramy czasowe: After 12 weeks of treatment
Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value
After 12 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 16
Ramy czasowe: After 16 weeks of treatment
Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value
After 16 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms in the Morning" at Week 4
Ramy czasowe: After 4 weeks of treatment
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value
After 4 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms This Morning" at Week 8
Ramy czasowe: After 8 weeks of treatment
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value
After 8 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms This Morning" at Week 12
Ramy czasowe: After 12 weeks of treatment
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value
After 12 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms This Morning" at Week 16
Ramy czasowe: After 16 weeks of treatment
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value
After 16 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 4
Ramy czasowe: After 4 weeks of treatment
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value
After 4 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 8
Ramy czasowe: After 8 weeks of treatment
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value
After 8 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 12
Ramy czasowe: After 12 weeks of treatment
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value
After 12 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 16
Ramy czasowe: After 16 weeks of treatment
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value
After 16 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 4
Ramy czasowe: After 4 weeks of treatment
Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value
After 4 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 8
Ramy czasowe: After 8 weeks of treatment
Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value
After 8 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 12
Ramy czasowe: After 12 weeks of treatment
Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value
After 12 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 16
Ramy czasowe: After 16 weeks of treatment
Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value
After 16 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 4
Ramy czasowe: After 4 weeks of treatment
Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value
After 4 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 8
Ramy czasowe: After 8 weeks of treatment
Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value
After 8 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 12
Ramy czasowe: After 12 weeks of treatment
Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value
After 12 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 16
Ramy czasowe: After 16 weeks of treatment
Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value
After 16 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 4
Ramy czasowe: After 4 weeks of treatment
Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value
After 4 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 8
Ramy czasowe: After 8 weeks of treatment
Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value
After 8 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 12
Ramy czasowe: After 12 weeks of treatment
Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value
After 12 weeks of treatment
Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 16
Ramy czasowe: After 16 weeks of treatment
Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value
After 16 weeks of treatment
Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 3
Ramy czasowe: After 6 weeks of treatment
Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 6 weeks of treatment
After 6 weeks of treatment
Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 4
Ramy czasowe: After 12 weeks of treatment
Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 12 weeks of treatment
After 12 weeks of treatment
Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 5
Ramy czasowe: After 16 weeks of treatment
Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 16 weeks od treatment
After 16 weeks of treatment
Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 3
Ramy czasowe: After 6 weeks of treatment
Morning pre-dose forced vital capacity as measured by spirometry after 6 weeks of treatment
After 6 weeks of treatment
Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 4
Ramy czasowe: After 12 weeks of treatment
Morning pre-dose forced vital capacity as measured by spirometry after 12 weeks of treatment
After 12 weeks of treatment
Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 5
Ramy czasowe: After 16 weeks of treatment
Morning pre-dose forced vital capacity as measured by spirometry after 16 weeks of treatment
After 16 weeks of treatment
Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Overall Score at Visit 3
Ramy czasowe: After 6 weeks of treatment
Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value
After 6 weeks of treatment
Mini-AQLQ Overall Score at Visit 4
Ramy czasowe: After 12 weeks of treatment
Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value
After 12 weeks of treatment
Mini-AQLQ Overall Score at Visit 5
Ramy czasowe: After 16 weeks of treatment
Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value
After 16 weeks of treatment
Systolic Blood Pressure in Conjunction With Spirometry at Visit 3
Ramy czasowe: After 6 weeks of treatment
Systolic blood pressure collected in conjunction with spirometry at 6 weeks
After 6 weeks of treatment
Systolic Blood Pressure in Conjunction With Spirometry at Visit 4
Ramy czasowe: After 12 weeks of treatment
Systolic blood pressure collected in conjunction with spirometry at 12 weeks
After 12 weeks of treatment
Systolic Blood Pressure in Conjunction With Spirometry at Visit 5
Ramy czasowe: After 16 weeks of treatment
Systolic blood pressure collected in conjunction with spirometry at 16 weeks
After 16 weeks of treatment
Diastolic Blood Pressure in Conjunction With Spirometry at Visit 3
Ramy czasowe: After 6 weeks of treatment
Diastolic blood pressure collected in conjunction with spirometry at 6 weeks
After 6 weeks of treatment
Diastolic Blood Pressure in Conjunction With Spirometry at Visit 4
Ramy czasowe: After 12 weeks of treatment
Diastolic blood pressure collected in conjunction with spirometry at 12 weeks
After 12 weeks of treatment
Diastolic Blood Pressure in Conjunction With Spirometry at Visit 5
Ramy czasowe: After 16 weeks of treatment
Diastolic blood pressure collected in conjunction with spirometry at 16 weeks
After 16 weeks of treatment
Pulse Rate in Conjunction With Spirometry at Visit 3
Ramy czasowe: After 6 weeks of treatment
Pulse rate collected in conjunction with spirometry at 6 weeks
After 6 weeks of treatment
Pulse Rate in Conjunction With Spirometry at Visit 4
Ramy czasowe: After 12 weeks of treatment
Pulse rate collected in conjunction with spirometry at 12 weeks
After 12 weeks of treatment
Pulse Rate in Conjunction With Spirometry at Visit 5
Ramy czasowe: After 16 weeks of treatment
Pulse rate collected in conjunction with spirometry at 16 weeks
After 16 weeks of treatment
Mean PEF Variability at Week 4
Ramy czasowe: After 4 weeks of treatment
PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%
After 4 weeks of treatment
Mean PEF Variability at Week 8
Ramy czasowe: After 8 weeks of treatment
PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%
After 8 weeks of treatment
Mean PEF Variability at Week 12
Ramy czasowe: After 12 weeks of treatment
PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%
After 12 weeks of treatment
Mean PEF Variability at Week 16
Ramy czasowe: After 16 weeks of treatment
PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%
After 16 weeks of treatment

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Boehringer Ingelheim

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 lipca 2006

Zakończenie podstawowe (Rzeczywisty)

1 września 2008

Daty rejestracji na studia

Pierwszy przesłany

7 lipca 2006

Pierwszy przesłany, który spełnia kryteria kontroli jakości

7 lipca 2006

Pierwszy wysłany (Oszacować)

10 lipca 2006

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

24 grudnia 2013

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

27 listopada 2013

Ostatnia weryfikacja

1 września 2013

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 205.342

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Placebo

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Kuwait

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

Subskrybuj